BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rifaximin (Xifaxan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rifaximin (Xifaxan)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07203846-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT07203846)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Modulation of Gut MicroF
 LORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patient
 s on Ticagrelor\nEstimated primary completion: 31 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07203846
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683936-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rifaximin (Xifaxan): Phase 1 readout est. (NCT07683936)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 1.\nStudy: Fecal Microbiota Transpl
 antation for the Treatment of Refractory Hepatic Encephalopathy After TIPS
  Surgery\nEstimated primary completion: 31 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07683936
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285785-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT07285785)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Rifaximin 200 mg Plus Or
 al Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea\n
 Estimated primary completion: 20 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07285785
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483737-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rifaximin (Xifaxan): Phase na readout est. (NCT06483737)
DESCRIPTION:Rifaximin (Xifaxan)\, phase na.\nStudy: Human Albumin Infusion 
 in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)\nEstimated pri
 mary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rifaximin-xifaxan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06483737
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312683-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT06312683)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Rifaximin for the Second
 ary Prevention of Recurrent Pouchitis\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifax
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6312683
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426705-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT07426705)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Effect of Multispecies P
 robiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patien
 ts With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo
 -controlled Trial\nEstimated primary completion: 15 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07426705
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538077-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT06538077)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: BCAA vs. Rifaximin in Pa
 tients With Cirrhosis for Secondary Prophylaxis of HE\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rifaximin-xifaxan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06538077
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058572-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Rifaximin (Xifaxan): Phase 2 readout est. (NCT06058572)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 2.\nStudy: Effect of Rifaximin on G
 ut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukem
 ia\nEstimated primary completion: 2 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06058572
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895433-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT07895433)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Rifaximin for Prevention
  of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric
  Anastomosis\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07895433
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882953-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rifaximin (Xifaxan): Phase 1 readout est. (NCT07882953)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 1.\nStudy: SIMBA in Irritable Bowel
  Syndrome (IBS)\nEstimated primary completion: December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07882953
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185932-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rifaximin (Xifaxan): Phase 1 readout est. (NCT07185932)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 1.\nStudy: Efficacy and Safety of R
 ifaximin in Treating MAFLD\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07185
 932
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381257-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rifaximin (Xifaxan): Phase 1 readout est. (NCT07381257)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 1.\nStudy: Efficacy and Safety of R
 ifaximin-α in Treating MASLD\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxa
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 381257
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180615-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Rifaximin (Xifaxan): Phase 4 readout est. (NCT07180615)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 4.\nStudy: Gut Decolonisation With 
 Neomycin/Metronidazole or Rifaximin Before Colon Surgery\nEstimated primar
 y completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rifaximin-xifaxan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07180615
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209371-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Rifaximin (Xifaxan): Phase 2 readout est. (NCT07209371)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 2.\nStudy: Rifaximin Versus No Inte
 rvention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of U
 ndetermined Significance\nEstimated primary completion: 1 May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07209371
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522255-6670@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rifaximin (Xifaxan): Phase 3 readout est. (NCT07522255)
DESCRIPTION:Rifaximin (Xifaxan)\, phase 3.\nStudy: Rifaximin Treatment in B
 loating Predominant Functional Bowel Disorders\nEstimated primary completi
 on: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rifaxi
 min-xifaxan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07522255
URL:https://assetmemo.bio/drug/rifaximin-xifaxan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
